Boston Bio

What does Boston Bio do?

Boston Bio Systems Ltd trades medical equipment and testing kits in the healthcare sector. As of March 2025, it reported net sales and profit of 0 Cr, with a market cap of Rs 5 Cr.

Overview:<BR>Boston Bio Systems Ltd is engaged in the trading of medical equipment, testing kits, and instruments within the healthcare services industry and operates as a micro-cap company.<BR><BR>History:<BR>The company was incorporated on April 17, 1995, and initially focused on share broking, investment, and trading in shares and derivatives. Currently, it is involved in trading goods related to healthcare. The latest quarterly results reported net sales and net profit of 0 Cr for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 5 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>Industry P/E: 53 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.00 <BR>Return on Equity: 0.00% <BR>Price to Book: 0.00 <BR><BR>Contact Details:<BR>Address: 17/B 4th Floor Mirzapur, Sandesh Commerical Complex Ahmedabad Gujarat : 380001 <BR>Tel: 91-9098433517 <BR>Email: bostonsystem@yahoo.com <BR>Website: http://www.bostonbiosystemltd.com

When is the next results date for Boston Bio?

No Upcoming Board Meetings

Who are in the management team of Boston Bio?

As of March 2017, the management team of Boston Bio includes Ramesh Kumar G Dave (Managing Director), Sanjay Sodani, Kushal Rathore, Amit Ashwinbhai Pandya, Ankit Sanjay Disoja, Narendra Mathurbhai Gandhi (all Non Executive Directors), and Seema Baghel (Additional Independent Director).

As of March 2017, the management team of Boston Bio includes the following individuals:<BR><BR>1. Ramesh Kumar G Dave - Managing Director<BR>2. Sanjay Sodani - Non Executive Director<BR>3. Kushal Rathore - Non Executive Independent Director<BR>4. Amit Ashwinbhai Pandya - Non Executive Director<BR>5. Ankit Sanjay Disoja - Non Executive Director<BR>6. Narendra Mathurbhai Gandhi - Non Executive Director<BR>7. Seema Baghel - Additional Director (Independent)<BR><BR>These members form the board of directors overseeing the company's operations.

Has Boston Bio declared dividend?

No Dividend History Available

What is the technical trend for Boston Bio?

As of June 5, 2025, Boston Bio's trend has shifted to bearish, supported by weekly MACD and Bollinger Bands, while daily moving averages confirm this trend, despite mixed signals from the KST and unclear indications from RSI and Dow Theory.

As of 5 June 2025, the technical trend for Boston Bio has changed from mildly bearish to bearish. The current stance is bearish with a strong indication from the weekly MACD and Bollinger Bands, both signaling bearish conditions. The daily moving averages also confirm a bearish trend. The KST shows a mixed signal with a bearish weekly reading and a bullish monthly reading, indicating some divergence in longer-term momentum. Overall, the lack of clear signals from the RSI and Dow Theory suggests a continuation of the bearish trend without any immediate reversal in sight.

Who are the peers of the Boston Bio?

Boston Bio's peers include Chennai Meena, Family Care, Vanta Bioscience, Gian Lifecare, Looks Health, Dr Lalchand Lab, Clinitech Lab, Dhanvantri Jeev., Ashram Online, and Sunrest Lifescie. Management risks vary, with Clinitech Lab and Sunrest Lifescie rated excellent, while returns range from Looks Health's 47.37% to Vanta Bioscience's -48.64%.

Peers: The peers of Boston Bio are Chennai Meena, Family Care, Vanta Bioscience, Gian Lifecare, Looks Health, Dr Lalchand. Lab, Clinitech Lab, Dhanvantri Jeev., Ashram Online, Sunrest Lifescie.<BR><BR>Quality Snapshot: Excellent management risk is observed at Clinitech Lab and Sunrest Lifescie, while Average management risk is found at Family Care and Dr Lalchand. Lab. Below Average management risk is noted for Gian Lifecare and Dhanvantri Jeev., while Chennai Meena, Vanta Bioscience, Looks Health, and Ashram Online do not qualify. In terms of Growth, Good growth is seen at Family Care and Looks Health, Average growth at Gian Lifecare, and Below Average growth at Dr Lalchand. Lab and Dhanvantri Jeev., while Chennai Meena, Vanta Bioscience, and the rest do not qualify. For Capital Structure, Excellent is noted at Family Care, Good at Gian Lifecare, Dr Lalchand. Lab, Clinitech Lab, and Dhanvantri Jeev., while Average is found at Family Care, and the rest do not qualify.<BR><BR>Return Snapshot: Looks Health has the highest 1-year return at 47.37%, while Vanta Bioscience has the lowest at -48.64%. Boston Bio's 1-year return is not available for comparison. Additionally, the six-month returns for Chennai Meena, Family Care, Gian Lifecare, Vanta Bioscience, Clinitech Lab, and Dhanvantri Jeev. are negative.

Who are the top shareholders of the Boston Bio?

The top shareholders of Boston Bio are Jyotshna Jagdishchandra Shah with 2.14% and Mayank Doshi with 2.6%. Individual investors hold a significant 85.33% of the shares, with no institutional or pledged promoter holdings reported.

The top shareholders of Boston Bio include Jyotshna Jagdishchandra Shah, who holds the highest promoter stake at 2.14%. The highest public shareholder is Mayank Doshi, with a holding of 2.6%. Additionally, individual investors collectively own a significant portion of the company, accounting for 85.33% of the shares. There are no institutional holdings or pledged promoter holdings reported.

How big is Boston Bio?

As of 24th July, Boston Bio Systems Ltd has a market capitalization of 5.00 Cr, with recent net sales of 0.39 Cr and a net profit loss of 0.68 Cr. Data for shareholder's funds and total assets is unavailable.

As of 24th July, <BR><BR>Market Cap: Boston Bio Systems Ltd has a market capitalization of 5.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 0.39 Cr, while the sum of Net Profit for the same period reflects a loss of 0.68 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is the latest annual period. However, data for Shareholder's Funds and Total Assets is unavailable.

How has been the historical performance of Boston Bio?

Boston Bio has experienced significant financial decline, with net sales dropping from 1.50 Cr in March 2016 to 0.19 Cr in March 2025, alongside increasing losses and negative cash flow. The company reported an operating profit of -0.55 Cr in March 2025, reflecting ongoing operational challenges.

Answer:<BR>The historical performance of Boston Bio shows significant fluctuations in its financial metrics over the years, particularly in net sales and profitability.<BR><BR>Breakdown:<BR>Boston Bio's net sales have seen a notable decline from 1.50 Cr in March 2016 to just 0.19 Cr in March 2025, with a complete absence of sales in the intervening years of March 2017, March 2018, and March 2024. The total operating income followed a similar trend, peaking at 1.50 Cr in March 2016 and dropping to 0.19 Cr in March 2025. The company has consistently reported no raw material costs or purchase of finished goods, indicating a lack of production activity. Total expenditure, however, increased to 0.74 Cr in March 2025, up from 0.14 Cr in March 2024, primarily driven by other expenses. This led to an operating profit (PBDIT) of -0.55 Cr in March 2025, reflecting a negative operating profit margin of -289.47%. The profit before tax and profit after tax also mirrored this negative trend, both standing at -0.55 Cr in March 2025. The earnings per share (EPS) further illustrate the company's struggles, with an EPS of -0.79 in March 2025 compared to -0.20 in March 2024. Cash flow from operating activities was -4.00 Cr in March 2025, indicating a significant cash outflow, while cash flow from financing activities was positive at 4.00 Cr, suggesting reliance on external financing to manage operations. Overall, Boston Bio's financial performance has been characterized by declining sales, increasing losses, and negative cash flow, highlighting ongoing challenges in its business operations.

Why is Boston Bio Systems Ltd falling/rising?

As of 18-Jan, Boston Bio Systems Ltd's stock price has risen to 9.25, reflecting a 4.99% increase. This growth is driven by strong recent performance and positive technical indicators, despite a decline in investor participation.

As of 18-Jan, Boston Bio Systems Ltd is experiencing a rise in its stock price, currently at 9.25, which reflects an increase of 0.44 or 4.99%. This upward movement can be attributed to several factors. Over the past week, the stock has gained 5.71%, significantly outperforming the Sensex, which saw a negligible change of -0.01%. In the last month, the stock has surged by 31.95%, while the Sensex has declined by 1.31%, indicating strong relative performance.<BR><BR>Additionally, Boston Bio Systems has shown consistent gains, with the stock rising for three consecutive days and achieving a total return of 11.18% during this period. The stock is also trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which is a positive technical indicator suggesting sustained upward momentum.<BR><BR>However, it is important to note that there has been a decline in investor participation, with delivery volume dropping by 81.41% compared to the 5-day average. Despite this decrease in participation, the stock remains liquid enough for trading, as indicated by its trading value.<BR><BR>Overall, the combination of strong recent performance, technical indicators, and relative outperformance against the benchmark suggests that Boston Bio Systems Ltd is rising in price.

Which are the latest news on Boston Bio?